Immune-Modified Glasgow Prognostic Score Predicts Therapeutic Effect of Pembrolizumab in Recurrent and Metastatic Head and Neck Cancer
This study demonstrates that the imGPS is an excellent predictive marker for the therapeutic effect and prognosis of pembrolizumab for RMHNC. The imGPS can be employed with daily blood tests, highlighting the potential to forecast the impact of the ICI with high reliability.
Authors
- Natsuko Ueda (ORCID: https://orcid.org/0000-0001-6204-6264)
- Ken Saijo (ORCID: https://orcid.org/0000-0003-0179-3789)
- Masashi Kuroki (ORCID: https://orcid.org/0000-0002-3199-009X)
- Takenori Ogawa (ORCID: https://orcid.org/0000-0003-1556-7328)
- Hirofumi Shibata (ORCID: https://orcid.org/0000-0002-7104-9456)
- Rina Kato
- Ryota Iinuma
- Masahiko Matsubara (ORCID: https://orcid.org/0000-0002-3608-6905)
- Ryo Kawaura (ORCID: https://orcid.org/0000-0002-8993-1834)
- Kosuke Terazawa (ORCID: https://orcid.org/0000-0002-0033-652X)
- Toshimitsu Ohashi (ORCID: https://orcid.org/0000-0003-2347-6709)
- Hiroshi Okuda (ORCID: https://orcid.org/0000-0001-8374-3798)
- Kenichi Mori
- Tatsuhiko Yamada
- Saki Akita
Institutions
- Tohoku University (JP)
- Ogaki Municipal Hospital (JP)
- Gifu University (JP)
Publication Details
- Journal
- Cancers
- Published
- 2024-12-03
- DOI
- https://doi.org/10.3390/cancers16234056
- Citations
- 1
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.28